The Committee was asked to consider information regarding clinical trial results including safety and efficacy, especially with regard to cardiovascular health, boxed warnings and contraindications, adverse events, combination therapy with a TZD and metformin or a sulfonylurea, as well as the importance of protecting beta-cells, lowering HgA1c, and avoiding complications of diabetes.